Stanford researchers have identified a biomarker on cartilage precursor cells that predicts which cells will develop into inflammation-resistant and functionally appropriate tissue for autologous transplants to treat osteoarthritis.
Researchers at Stanford have discovered that treatment with JNK II inhibitor and IBMX has a synergistic therapeutic effect against osteoarthritis (OA).